Laboratory Monitoring for Testosterone Enanthate and Oxandrolone (Anavar)
Patients taking testosterone enanthate and oxandrolone require comprehensive laboratory monitoring at baseline, 3-6 months after initiation, and then annually, with critical attention to hematocrit, liver function, lipid profile, testosterone levels, and PSA (in men ≥40 years). This monitoring protocol is essential to prevent serious adverse effects including polycythemia, hepatotoxicity, cardiovascular complications, and to detect potential prostate abnormalities.
Core Laboratory Tests
Hematocrit/Hemoglobin (Most Critical)
- Check at baseline, 3-6 months, then annually 1
- Stop therapy immediately if hematocrit >54% until it decreases to safe levels 1
- Both testosterone and oxandrolone cause dose-dependent increases in hemoglobin, with greater increases in older men 1
- Evaluate for hypoxia and sleep apnea if hematocrit becomes elevated 1
- Reinitiate with reduced dose only after hematocrit normalizes 1
Critical pitfall: Polycythemia is one of the most common and dangerous adverse effects of combined androgen therapy. The risk is substantially higher when using two androgenic agents simultaneously.
Liver Function Tests (Essential for Oxandrolone)
- Obtain periodically due to hepatotoxicity associated with 17-alpha-alkylated androgens like oxandrolone 2
- Oxandrolone specifically carries hepatotoxicity risk that testosterone enanthate does not 2
- Monitor more frequently (every 3-6 months) given the combination therapy
Lipid Profile
- Perform periodically with therapy adjustment based on results 2
- Androgenic anabolic steroids increase LDL and decrease HDL 2
- Testosterone enanthate at 200mg/week causes 15-20% decrease in HDL-cholesterol 3
- Exercise particular caution in patients with cardiovascular disease history or risk factors 2
Testosterone Levels
- Measure 3-6 months after initiation, then adjust dosing 1
- For injectable testosterone enanthate: measure midway between injections 1
- Target mid-normal range (400-700 ng/dL) 1
- Adjust dose/frequency if testosterone >700 ng/dL or <400 ng/dL 1
Prostate Monitoring (Age-Dependent)
For men ≥40 years with baseline PSA >0.6 ng/mL:
- Perform digital rectal examination and check PSA at baseline, 3-6 months, then per age-appropriate screening guidelines 1
- Obtain urological consultation if:
Additional Monitoring Considerations
Coagulation Parameters
- Monitor INR/PT closely if patient takes warfarin 2
- Oxandrolone causes dramatic increases in INR (up to 5.5-fold warfarin dose reduction required) 2
- Both agents suppress clotting factors II, V, VII, and X 2
- Check more frequently when initiating, adjusting, or discontinuing therapy 2
Blood Glucose Monitoring
- Oxandrolone may inhibit metabolism of oral hypoglycemic agents 2
- Monitor glucose more closely in diabetic patients
Thyroid Function
- Anabolic steroids decrease thyroxine-binding globulin 2
- May see decreased total T4 with unchanged free thyroid hormone levels 2
- Consider checking if symptoms suggest thyroid dysfunction
Monitoring Schedule Algorithm
Baseline (Before Starting):
- Complete blood count (CBC) with hematocrit
- Comprehensive metabolic panel (liver function)
- Lipid profile
- Testosterone level (total, consider free testosterone)
- PSA and digital rectal examination (if ≥40 years)
- INR/PT (if on anticoagulation)
- Fasting glucose
At 3-6 Months:
- CBC with hematocrit
- Liver function tests
- Lipid profile
- Testosterone level (midway between injections)
- PSA (if ≥40 years)
- INR/PT (if on anticoagulation)
Annually Thereafter:
- CBC with hematocrit
- Liver function tests
- Lipid profile
- Testosterone level
- PSA per age-appropriate guidelines (if ≥40 years)
Critical Safety Considerations
Absolute contraindications requiring immediate cessation:
- Hematocrit >54% 1
- Significant PSA elevation or abnormal digital rectal examination 1
- Evidence of hepatotoxicity
- Uncontrolled cardiovascular disease 4
Common pitfall: Many clinicians monitor testosterone levels but neglect the critical importance of hematocrit monitoring. Polycythemia can develop insidiously and poses serious thrombotic risk, particularly with combination androgen therapy.
Special consideration: The combination of testosterone enanthate and oxandrolone creates additive androgenic effects and potentially compounded risks. The monitoring frequency suggested here (every 3-6 months initially) is more conservative than for testosterone monotherapy and is appropriate given the dual androgen exposure and oxandrolone's hepatotoxicity risk 2.